REBLOZYL® (luspatercept-aamt) is a prescription medicine used to treat anemia (low red blood cells) without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
It is not known if REBLOZYL is safe or effective in children under 18 years of age.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Treating anemia is an important part of managing myelodysplastic syndromes (MDS).
REBLOZYL is a treatment option that helps manage your anemia associated with lower-risk MDS.
REBLOZYL is a prescription medicine for injection, and is used to treat anemia (low red blood cells) in adults with:
REBLOZYL is not a substitute for RBC transfusions in people who need immediate treatment for anemia.
It is not known if REBLOZYL is safe or effective in children under 18 years of age. REBLOZYL may help lower the number of RBC transfusions you need.
An EMA helps immature RBCs (called erythroid cells) develop and become mature, working RBCs. This may result in more healthy RBCs and improve anemia.
It’s important that you learn about how REBLOZYL works before starting treatment. This can help you better understand why your doctor prescribed REBLOZYL. It can also make you feel more confident when talking with your healthcare team.
This means that there are more mature RBCs in the bloodstream.
Starting a different treatment can be a hopeful time. It might also bring some anxiety about what happens next, and there can be a lot to learn when you get started. To help with this time of change, there are resources and support to help you get the most from your treatment.
Stay connected to the
support you need
Your REBLOZYL Connection is an educational program designed to help you understand your treatment with REBLOZYL, and provide resources that allow you to be more active role with your care.